pipette
ENEnglish

Cerebrospinal fluid dopa-decarboxylase is a biomarker of dopaminergic dysfunction

S. Sperandei, F. Paolini Paoletti, M. De Pauw, L. Gaetani, C. Tranfaglia, J. Goossens, E. Stoops, E. Vanmechelen, L. Parnetti, G. Bellomo, D. Chiasserini

PreprintUso en el mundo real

En palabras de los autores

Background. Nigrostriatal dopaminergic dysfunction, a biological anchor of Parkinson's disease (PD), is routinely assessed using single-photon emission computed tomography of the dopamine transporter (DaT-SPECT). Dopa decarboxylase (DDC) in cerebrospinal fluid (CSF) is a promising biomarker of dopaminergic dysfunction, but its association with DaT-SPECT has to be demonstrated. Objectives. To investigate the association of CSF DDC with DaT-SPECT. Methods. We first analysed proteomic and DaT-SPECT data from the Parkinson's Progression Markers Initiative (PPMI), including PD (n=891), prodromal PD (n=867) and healthy controls (n=161). We then verified this association in a single-center clinical cohort (UNIPG), including PD/Dementia with Lewy Bodies (DLB) (n=78), atypical parkinsonisms (AP, n=11), other neurodegenerative diseases (OND, n=25) and controls (CTRL, n=40). Here, CSF DDC was measured by a novel fully automated quantitative immunoassay. Results. In PPMI, among 129 proteins assessed, DDC showed the strongest association with DaT-SPECT ({beta} = -0.132, FDR = 6.92 x 10-33). Across PPMI and UNIPG cohorts, DDC correlated with striatal binding ratio (SBR) ({rho} = -0.377, P < 0.001; {rho} = -0.466, P < 0.001, respectively) and accurately discriminated positive from negative scans (AUC 0.811, 95% CI 0.762-0.859; AUC 0.870, 95% CI 0.777-0.963, respectively). In PPMI prodromal cases, higher DDC predicted faster motor progression. In UNIPG, DDC distinguished PD/DLB and AP from OND and CTRL groups (AUC 0.830, 95% CI 0.764-0.896), independently of dopaminergic treatment. Conclusion. CSF DDC reflects nigrostriatal dopaminergic dysfunction, representing a potential quantitative biochemical alternative to DaT-SPECT that might be readily implemented via automated immunoassays.

Resultado principalEl resumen no menciona limitaciones.

Apareció: jueves, 15 de octubre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.13.26364985